Serena Williams, the legendary tennis champion, has publicly admitted to using GLP-1 weight-loss medication, resulting in a 31-pound weight loss, as part of her effort to destigmatize such treatments for health reasons. This revelation was made through interviews and a campaign launch on August 21, 2025, highlighting her personal journey and advocacy.
Serena Williams, a 23-time Grand Slam winner, disclosed her use of GLP-1 medications during appearances on the ‘Today’ show and in People magazine. She explained that this decision came after years of struggling with weight management post-pregnancy, despite her active lifestyle as a professional athlete. The confession was timed with the launch of a multi-year campaign for telehealth company Ro, where Williams serves as a patient ambassador.
The announcement occurred on August 21, 2025, through major media outlets including Fox News, Bloomberg, and CBS News. Williams participated in interviews and promotional activities primarily in New York City, where the campaign was unveiled. This widespread coverage ensured the story reached a broad audience quickly.
Williams turned to GLP-1 medication after the birth of her second daughter, citing persistent health issues such as joint pain and blood sugar imbalances that traditional exercise and diet could not resolve. She emphasized that her motivation was not about appearance but about achieving a healthier weight for her well-being. Her goal is to challenge the stigma that using medication for weight loss is a shortcut or failure.
She began her GLP-1 regimen approximately a year ago, after ceasing breastfeeding, but initially paused due to uncertainties. In January 2025, she recommitted to the treatment under the guidance of Ro, which provides prescriptions for drugs like Ozempic and Wegovy. Williams detailed her experience with the medication, noting a loss of 31 pounds over eight months, and shared that she co-wrote the campaign’s voiceover to authentically represent her journey.
The impact of Williams’ confession is significant, as it brings attention to the challenges many women face with weight loss after childbirth, especially athletes. By speaking openly, she aims to normalize the use of medical interventions for weight management and reduce shame associated with it. This could influence public perception and encourage more discussions about health options.
Looking ahead, Williams will continue her advocacy through the Ro campaign, which includes digital, broadcast, and out-of-home advertising, such as placements in Times Square and at the US Open. She hopes her story will inspire others to seek help without judgment and promote a broader understanding of weight-loss treatments.